Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 267Oxaliplatin 194Carboplatin 189Capecitabine 183Docetaxel 176apatinib 164Paclitaxel 158Bevacizumab 155Gemcitabine 154Radiotherapy 146camrelizumab 145Fluorouracil 144Cyclophosphamide 123Irinotecan 119Drug Therapy 118sintilimab 107Etoposide 99anlotinib 90S 1 (combination) 88Leucovorin 85pembrolizumab 82Pemetrexed 78Doxorubicin 77toripalimab 76tislelizumab 75Dexamethasone 70Trastuzumab 65Neoadjuvant Therapy 64Rituximab 62Cetuximab 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Unknown × 64Cu-DOTATATE × Clear all
NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Rigshospitalet, Denmark

Phase 2 Unknown
200 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡